Goldman Sachs raises target for Argenx stock to EUR 982.00

Published on 10/07/2026 at 09:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 sales rose 60 percent to USD 1.50 billion. Argenx stock costs EUR 826.60 on October 7, 2026 versus EUR 828.90, minus 0.28 percent.

Architekturaufnahme eines modernen Biotechnologie-Campus in Belgien, Glas-Stahl-Gebäude mit Dachgärten, Radfahrer auf baumgesäumter Allee, nordeeuropäischer Himmel — Argenx NL0010832176 moderner belgischer Biotech-Campus mit Glasfassaden und Radfahrern unter bewölktem Herbsthimmel, Illustration mit AI erstellt.

Argenx (ISIN NL0010832176) was trading at EUR 826.60 at Lang & Schwarz on October 7, 2026 at 9:11 a.m. CEST, down 0.28 percent from the prior close of EUR 828.90. The latest analyst action came from Goldman Sachs, which raised its target from EUR 973.00 to EUR 982.00 and kept a Buy rating on September 25, 2026, according to finanzen.ch.

Goldman lifts its valuation mark

The EUR 9.00 increase puts the new target 18.80 percent above the Lang & Schwarz price, calculated against EUR 826.60. Goldman analyst Rajan Sharma linked the view to expectations for Vyvgart, argenx's leading immunology product, ahead of the company's October 22 quarterly report, as reported by finanzen.ch.

The target revision is modest relative to the existing valuation call: the price objective rose 0.93 percent from EUR 973.00, while the rating stayed at Buy. That combination gives the note a measured tone rather than a wholesale change in Goldman Sachs' view.

Sales growth remains the operating anchor

argenx reported second-quarter 2026 sales of USD 1.50 billion, up 60 percent from the same quarter a year earlier, according to Quartr. The company said its growth was driven by VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with new launches adding to the commercial base.

The second-quarter figure matters because the October 22 update will test whether the 60 percent sales growth rate is continuing into the second half of 2026. Argenx's investor materials identify VYVGART and its broader pipeline as central to the company's immunology strategy, while its listings include Euronext Brussels and Nasdaq, according to the argenx investor page.

October report sets the next test

Argenx's next earnings date is listed as October 22, 2026 by StockAnalysis. For investors, the key issue is whether product expansion can support the second-quarter sales pace while the pipeline supplies additional growth beyond VYVGART.

Stock trades below its prior close

At Lang & Schwarz, Argenx stood at EUR 826.60 on October 7, 2026 at 9:11 a.m. CEST, down 0.28 percent versus the prior close of EUR 828.90. The company had a market capitalization of USD 57.9 billion as of October 6, 2026, while its primary listing is on Euronext Brussels and its sector is biotechnology. The further course of trading is shown by the continuously updated real-time quote of Argenx stock.